vs
Side-by-side financial comparison of Bio-Techne (TECH) and TENNANT CO (TNC). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($311.4M vs $291.6M, roughly 1.1× TENNANT CO). Bio-Techne runs the higher net margin — 16.4% vs -1.5%, a 17.9% gap on every dollar of revenue. On growth, Bio-Techne posted the faster year-over-year revenue change (-1.5% vs -11.3%). Over the past eight quarters, Bio-Techne's revenue compounded faster (1.3% CAGR vs -3.2%).
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
The Tennant Company (TNC:NYQ) is a company with about 4000 employees that provides cleaning products. It is a company that is listed in the New York Stock Exchange.
TECH vs TNC — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $311.4M | $291.6M |
| Net Profit | $51.0M | $-4.4M |
| Gross Margin | 66.9% | 34.6% |
| Operating Margin | 24.2% | -1.4% |
| Net Margin | 16.4% | -1.5% |
| Revenue YoY | -1.5% | -11.3% |
| Net Profit YoY | 126.0% | -166.7% |
| EPS (diluted) | $0.32 | $-0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $311.4M | — | ||
| Q4 25 | $295.9M | $291.6M | ||
| Q3 25 | — | $303.3M | ||
| Q2 25 | $317.0M | $318.6M | ||
| Q1 25 | $316.2M | $290.0M | ||
| Q4 24 | $297.0M | $328.9M | ||
| Q3 24 | $289.5M | $315.8M | ||
| Q2 24 | $306.1M | $331.0M |
| Q1 26 | $51.0M | — | ||
| Q4 25 | $38.0M | $-4.4M | ||
| Q3 25 | — | $14.9M | ||
| Q2 25 | $-17.7M | $20.2M | ||
| Q1 25 | $22.6M | $13.1M | ||
| Q4 24 | $34.9M | $6.6M | ||
| Q3 24 | $33.6M | $20.8M | ||
| Q2 24 | $40.6M | $27.9M |
| Q1 26 | 66.9% | — | ||
| Q4 25 | 64.6% | 34.6% | ||
| Q3 25 | — | 42.7% | ||
| Q2 25 | 62.7% | 42.1% | ||
| Q1 25 | 67.9% | 41.4% | ||
| Q4 24 | 65.3% | 41.3% | ||
| Q3 24 | 63.2% | 42.4% | ||
| Q2 24 | 66.4% | 43.1% |
| Q1 26 | 24.2% | — | ||
| Q4 25 | 18.4% | -1.4% | ||
| Q3 25 | — | 7.4% | ||
| Q2 25 | -7.5% | 9.6% | ||
| Q1 25 | 12.2% | 6.8% | ||
| Q4 24 | 16.0% | 2.3% | ||
| Q3 24 | 13.8% | 9.7% | ||
| Q2 24 | 15.0% | 11.7% |
| Q1 26 | 16.4% | — | ||
| Q4 25 | 12.8% | -1.5% | ||
| Q3 25 | — | 4.9% | ||
| Q2 25 | -5.6% | 6.3% | ||
| Q1 25 | 7.1% | 4.5% | ||
| Q4 24 | 11.7% | 2.0% | ||
| Q3 24 | 11.6% | 6.6% | ||
| Q2 24 | 13.3% | 8.4% |
| Q1 26 | $0.32 | — | ||
| Q4 25 | $0.24 | $-0.21 | ||
| Q3 25 | — | $0.80 | ||
| Q2 25 | $-0.11 | $1.08 | ||
| Q1 25 | $0.14 | $0.69 | ||
| Q4 24 | $0.22 | $0.35 | ||
| Q3 24 | $0.21 | $1.09 | ||
| Q2 24 | $0.26 | $1.45 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $209.8M | — |
| Total DebtLower is stronger | — | $273.2M |
| Stockholders' EquityBook value | $2.1B | $601.6M |
| Total Assets | $2.6B | $1.3B |
| Debt / EquityLower = less leverage | — | 0.45× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $209.8M | — | ||
| Q4 25 | $172.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $162.2M | — | ||
| Q1 25 | $140.7M | — | ||
| Q4 24 | $177.5M | — | ||
| Q3 24 | $187.5M | — | ||
| Q2 24 | $152.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | $260.0M | $273.2M | ||
| Q3 25 | — | $238.3M | ||
| Q2 25 | $346.0M | $213.4M | ||
| Q1 25 | $330.0M | $213.3M | ||
| Q4 24 | $300.0M | $198.2M | ||
| Q3 24 | $300.0M | $208.6M | ||
| Q2 24 | $319.0M | $205.6M |
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.0B | $601.6M | ||
| Q3 25 | — | $640.9M | ||
| Q2 25 | $1.9B | $651.9M | ||
| Q1 25 | $2.0B | $624.4M | ||
| Q4 24 | $2.1B | $620.8M | ||
| Q3 24 | $2.1B | $647.2M | ||
| Q2 24 | $2.1B | $624.6M |
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.5B | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $2.6B | $1.2B | ||
| Q1 25 | $2.6B | $1.2B | ||
| Q4 24 | $2.7B | $1.2B | ||
| Q3 24 | $2.7B | $1.2B | ||
| Q2 24 | $2.7B | $1.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.13× | 0.45× | ||
| Q3 25 | — | 0.37× | ||
| Q2 25 | 0.18× | 0.33× | ||
| Q1 25 | 0.16× | 0.34× | ||
| Q4 24 | 0.14× | 0.32× | ||
| Q3 24 | 0.14× | 0.32× | ||
| Q2 24 | 0.15× | 0.33× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $14.2M |
| Free Cash FlowOCF − Capex | — | $9.7M |
| FCF MarginFCF / Revenue | — | 3.3% |
| Capex IntensityCapex / Revenue | — | 1.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $43.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $14.2M | ||
| Q3 25 | — | $28.7M | ||
| Q2 25 | $98.2M | $22.5M | ||
| Q1 25 | $41.1M | $-400.0K | ||
| Q4 24 | $84.3M | $37.5M | ||
| Q3 24 | $63.9M | $30.7M | ||
| Q2 24 | $75.5M | $18.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | $9.7M | ||
| Q3 25 | — | $22.3M | ||
| Q2 25 | $93.3M | $18.7M | ||
| Q1 25 | $31.0M | $-7.4M | ||
| Q4 24 | $77.5M | $28.1M | ||
| Q3 24 | $54.7M | $26.4M | ||
| Q2 24 | $57.5M | $14.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.3% | ||
| Q3 25 | — | 7.4% | ||
| Q2 25 | 29.4% | 5.9% | ||
| Q1 25 | 9.8% | -2.6% | ||
| Q4 24 | 26.1% | 8.5% | ||
| Q3 24 | 18.9% | 8.4% | ||
| Q2 24 | 18.8% | 4.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.5% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | 1.5% | 1.2% | ||
| Q1 25 | 3.2% | 2.4% | ||
| Q4 24 | 2.3% | 2.9% | ||
| Q3 24 | 3.2% | 1.4% | ||
| Q2 24 | 5.9% | 1.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.93× | ||
| Q2 25 | — | 1.11× | ||
| Q1 25 | 1.82× | -0.03× | ||
| Q4 24 | 2.42× | 5.68× | ||
| Q3 24 | 1.90× | 1.48× | ||
| Q2 24 | 1.86× | 0.67× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
TNC
| Equipment Sales | $165.5M | 57% |
| Parts And Consumables | $69.1M | 24% |
| Service And Other | $57.0M | 20% |
